RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTIONS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists seek perfect timing for RSV booster shots in seniors
⭐️ VACCINE ⭐️ OngoingThis study aims to find the best time for older adults to get a booster dose of the RSV vaccine after their first shot. It will follow over 10,000 participants for about five years to see how long the vaccine's protection lasts and monitor its safety. The study also offers the re…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 25, 2026 14:08 UTC
-
First human test of mRNA RSV shot begins
⭐️ VACCINE ⭐️ OngoingThis is the first time this new mRNA vaccine for Respiratory Syncytial Virus (RSV) is being tested in people. The study aims to check if different doses are safe and if they trigger a good immune response in 213 healthy adults aged 18-45. Researchers will closely monitor for side…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 25, 2026 14:08 UTC
-
New shot aims to shield seniors from dangerous RSV virus
⭐️ VACCINE ⭐️ OngoingThis study is testing an investigational vaccine designed to protect adults aged 60 and older from Respiratory Syncytial Virus (RSV) infections. Researchers are checking how safe the vaccine is, how well it triggers an immune response, and how long that protection might last—up t…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 20, 2026 14:47 UTC